238 related articles for article (PubMed ID: 30097569)
1. Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC.
Arasada RR; Shilo K; Yamada T; Zhang J; Yano S; Ghanem R; Wang W; Takeuchi S; Fukuda K; Katakami N; Tomii K; Ogushi F; Nishioka Y; Talabere T; Misra S; Duan W; Fadda P; Rahman MA; Nana-Sinkam P; Evans J; Amann J; Tchekneva EE; Dikov MM; Carbone DP
Nat Commun; 2018 Aug; 9(1):3198. PubMed ID: 30097569
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of β-Catenin enhances the anticancer effect of irreversible EGFR-TKI in EGFR-mutated non-small-cell lung cancer with a T790M mutation.
Togashi Y; Hayashi H; Terashima M; de Velasco MA; Sakai K; Fujita Y; Tomida S; Nakagawa K; Nishio K
J Thorac Oncol; 2015 Jan; 10(1):93-101. PubMed ID: 25384171
[TBL] [Abstract][Full Text] [Related]
3. DDX3X induces primary EGFR-TKI resistance based on intratumor heterogeneity in lung cancer cells harboring EGFR-activating mutations.
Nozaki K; Kagamu H; Shoji S; Igarashi N; Ohtsubo A; Okajima M; Miura S; Watanabe S; Yoshizawa H; Narita I
PLoS One; 2014; 9(10):e111019. PubMed ID: 25343452
[TBL] [Abstract][Full Text] [Related]
4. MiR-200c-3p suppression is associated with development of acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR mutant non-small cell lung cancer via a mediating epithelial-to-mesenchymal transition (EMT) process.
Wang HY; Liu YN; Wu SG; Hsu CL; Chang TH; Tsai MF; Lin YT; Shih JY
Cancer Biomark; 2020; 28(3):351-363. PubMed ID: 32417760
[TBL] [Abstract][Full Text] [Related]
5. Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition.
Soucheray M; Capelletti M; Pulido I; Kuang Y; Paweletz CP; Becker JH; Kikuchi E; Xu C; Patel TB; Al-Shahrour F; Carretero J; Wong KK; Jänne PA; Shapiro GI; Shimamura T
Cancer Res; 2015 Oct; 75(20):4372-83. PubMed ID: 26282169
[TBL] [Abstract][Full Text] [Related]
6. Circulating Proteoglycan Endocan Mediates EGFR-Driven Progression of Non-Small Cell Lung Cancer.
Yang YC; Pan KF; Lee WJ; Chang JH; Tan P; Gu CC; Chang WM; Yang SF; Hsiao M; Hua KT; Chien MH
Cancer Res; 2020 Aug; 80(16):3292-3304. PubMed ID: 32561533
[TBL] [Abstract][Full Text] [Related]
7. Alisertib inhibits migration and invasion of EGFR-TKI resistant cells by partially reversing the epithelial-mesenchymal transition.
Wang CY; Lee MH; Kao YR; Hsiao SH; Hong SY; Wu CW
Biochim Biophys Acta Mol Cell Res; 2021 May; 1868(6):119016. PubMed ID: 33744274
[TBL] [Abstract][Full Text] [Related]
8. Polyphyllin I Overcomes EMT-Associated Resistance to Erlotinib in Lung Cancer Cells via IL-6/STAT3 Pathway Inhibition.
Lou W; Chen Y; Zhu KY; Deng H; Wu T; Wang J
Biol Pharm Bull; 2017 Aug; 40(8):1306-1313. PubMed ID: 28515374
[TBL] [Abstract][Full Text] [Related]
9. The regulatory role of APE1 in epithelial-to-mesenchymal transition and in determining EGFR-TKI responsiveness in non-small-cell lung cancer.
Yang X; Peng Y; Jiang X; Lu X; Duan W; Zhang S; Dai N; Shan J; Feng Y; Li X; Cheng Y; Yang Y; Baugh L; Tell G; Wang D; Li M
Cancer Med; 2018 Sep; 7(9):4406-4419. PubMed ID: 30109782
[TBL] [Abstract][Full Text] [Related]
10. P21-activated kinase 2-mediated β-catenin signaling promotes cancer stemness and osimertinib resistance in EGFR-mutant non-small-cell lung cancer.
Yi Y; Li P; Huang Y; Chen D; Fan S; Wang J; Yang M; Zeng S; Deng J; Lv X; Luo K; He Z; Liu H
Oncogene; 2022 Sep; 41(37):4318-4329. PubMed ID: 35986102
[TBL] [Abstract][Full Text] [Related]
11. Stem cell-like ALDH(bright) cellular states in EGFR-mutant non-small cell lung cancer: a novel mechanism of acquired resistance to erlotinib targetable with the natural polyphenol silibinin.
Corominas-Faja B; Oliveras-Ferraros C; Cuyàs E; Segura-Carretero A; Joven J; Martin-Castillo B; Barrajón-Catalán E; Micol V; Bosch-Barrera J; Menendez JA
Cell Cycle; 2013 Nov; 12(21):3390-404. PubMed ID: 24047698
[TBL] [Abstract][Full Text] [Related]
12. Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer.
Sato H; Yamamoto H; Sakaguchi M; Shien K; Tomida S; Shien T; Ikeda H; Hatono M; Torigoe H; Namba K; Yoshioka T; Kurihara E; Ogoshi Y; Takahashi Y; Soh J; Toyooka S
Cancer Sci; 2018 Oct; 109(10):3183-3196. PubMed ID: 30098066
[TBL] [Abstract][Full Text] [Related]
13. Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer.
Tong X; Tanino R; Sun R; Tsubata Y; Okimoto T; Takechi M; Isobe T
Respir Res; 2019 Dec; 20(1):270. PubMed ID: 31791326
[TBL] [Abstract][Full Text] [Related]
14. Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer.
Raoof S; Mulford IJ; Frisco-Cabanos H; Nangia V; Timonina D; Labrot E; Hafeez N; Bilton SJ; Drier Y; Ji F; Greenberg M; Williams A; Kattermann K; Damon L; Sovath S; Rakiec DP; Korn JM; Ruddy DA; Benes CH; Hammerman PS; Piotrowska Z; Sequist LV; Niederst MJ; Barretina J; Engelman JA; Hata AN
Oncogene; 2019 Sep; 38(37):6399-6413. PubMed ID: 31324888
[TBL] [Abstract][Full Text] [Related]
15. Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non-small cell lung cancer.
Ali A; Levantini E; Teo JT; Goggi J; Clohessy JG; Wu CS; Chen L; Yang H; Krishnan I; Kocher O; Zhang J; Soo RA; Bhakoo K; Chin TM; Tenen DG
EMBO Mol Med; 2018 Mar; 10(3):. PubMed ID: 29449326
[TBL] [Abstract][Full Text] [Related]
16. Shisa3 brakes resistance to EGFR-TKIs in lung adenocarcinoma by suppressing cancer stem cell properties.
Si J; Ma Y; Bi JW; Xiong Y; Lv C; Li S; Wu N; Yang Y
J Exp Clin Cancer Res; 2019 Dec; 38(1):481. PubMed ID: 31801598
[TBL] [Abstract][Full Text] [Related]
17. ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in
Okura N; Nishioka N; Yamada T; Taniguchi H; Tanimura K; Katayama Y; Yoshimura A; Watanabe S; Kikuchi T; Shiotsu S; Kitazaki T; Nishiyama A; Iwasaku M; Kaneko Y; Uchino J; Uehara H; Horinaka M; Sakai T; Tanaka K; Kozaki R; Yano S; Takayama K
Clin Cancer Res; 2020 May; 26(9):2244-2256. PubMed ID: 31953310
[TBL] [Abstract][Full Text] [Related]
18. Targeting the IL-1β/EHD1/TUBB3 axis overcomes resistance to EGFR-TKI in NSCLC.
Huang J; Lan X; Wang T; Lu H; Cao M; Yan S; Cui Y; Jia D; Cai L; Xing Y
Oncogene; 2020 Feb; 39(8):1739-1755. PubMed ID: 31740781
[TBL] [Abstract][Full Text] [Related]
19. Acquisition of cancer stem cell-like properties in non-small cell lung cancer with acquired resistance to afatinib.
Hashida S; Yamamoto H; Shien K; Miyoshi Y; Ohtsuka T; Suzawa K; Watanabe M; Maki Y; Soh J; Asano H; Tsukuda K; Miyoshi S; Toyooka S
Cancer Sci; 2015 Oct; 106(10):1377-84. PubMed ID: 26202045
[TBL] [Abstract][Full Text] [Related]
20. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]